Alira Health Joins EMIG to Advance Market Access in the UK

News
Published on:
April 5, 2023

We are pleased to announce that Alira Health has joined the Ethical Medicines Industry Group (EMIG), a multi-stakeholder network and trade association that represents the interests of life sciences companies in the UK.

The growth and sustainability of the UK health ecosystem is critical to providing patients with access to quality care, and that ecosystem growth is central to EMIG’s mission. At Alira Health, we put patients at the centre of everything we do."
Richard Charter Vice President MedTech Market Access, Europe & Asia Pacific

EMIG represents its over 300 industry members and associate members to government, the NHS, regulatory bodies, and academic research organisations in order to ensure that patients are able to access a wide range of innovative medicines. And EMIG encompasses the breadth of the health and medicines ecosystem in the UK, which makes it a vital platform for greater knowledge and ideas exchange. Alira Health’s access to this platform strengthens our ability to serve our clients in the UK while advancing our global market access solutions.

“The growth and sustainability of the UK health ecosystem is critical to providing patients with access to quality care, and that ecosystem growth is central to EMIG’s mission. At Alira Health, we put patients at the centre of everything we do. Working with EMIG aligns us with a valuable source of expertise and knowledge that will benefit our clients as we work together to get much-needed products to patients in the UK market,” said Richard Charter, Vice President MedTech Market Access – Europe & Asia Pacific.

Membership in EMIG will enable Alira Health to stay current on new UK developments and those on the horizon and to better prepare our clients for challenges and opportunities ahead in the UK market.

This news follows on the heels of Alira Health’s partnership with leading UK market access specialist consultancy Policy Matters, as we further align with resources for the complex and challenging UK market.

Related news

Events May 16, 2023
PSI 2023 Conference
We're excited to talk orphan drugs and rare diseases at the World Orphan Drug Congress in Washington, D.C.
Orphan Drug Pharma Rare Disease UK
Blog April 17, 2023
Reimbursement of Rare Disease Drugs in Italy: Challenges and Hopes for the Future
When it comes to rare diseases, Italy has done a good job in bringing EMA-approved drugs, including orphan drugs, to the Italian market. But  multiple challenges exist, many of which(...)
Italy Market Access Pharma Rare Disease Real-World Evidence (RWE)
Blog April 17, 2023
Pharmaceutical Market Access in the UK: A Changing Landscape
Start reading this interview with Rachel Fyson to gain insight into the changing landscape of market access in the United Kingdom.
Market Access Pharma UK
Blog April 14, 2023
Lifecycle Optimization: The Path to Commercial Success
Pharmaceutical and biotech companies constantly focus on product innovation. But how can you also increase your effectiveness in order to be as commercially competitive and efficient as possible?
Market Access MedTech Pharma
News April 5, 2023
Alira Health Joins EMIG to Advance Market Access in the UK
We are pleased to announce that Alira Health has joined the Ethical Medicines Industry Group (EMIG), a multi-stakeholder network and trade association that represents the interests(...)
Market Access Patient Centricity UK
Blog March 20, 2023
The State of Market Access in Italy 2023
To learn about the state of market access in Italy today, we spoke with Giovanni Firenze, Director of Market Access Italy for Alira Health, who attended the recent 2023 Conferenza Nazionale(...)
Drug Development Italy Market Access Pharma
Events March 6, 2023
World EPA Congress 2023
We are pleased to share that we will be participating in World EPA Congress 2023 as speakers and sponsors. World Evidence, Pricing and Access Congress is Europe’s largest congress(...)
Biotech Market Access Pharma Real-World Evidence (RWE)
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.